Immune Response Pharma Companies Trials Vaccine 
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
World of DTC Marketing
AUGUST 3, 2020
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. Personally I would want to know as much as I can before I ask for the vaccine but I also know that greed can make people do stupid things and there is a lot of money at stake here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.
World of DTC Marketing
SEPTEMBER 28, 2020
J&J’s COVID vaccine is being promoted by the media to have a 98% immune system response. Will it lead to an early approval with limited testing or will J&J ensure the vaccine goes thru thorough testing? government to manufacture 100 million doses of its investigational COVID-19 vaccine.
pharmaphorum
SEPTEMBER 20, 2022
Ben Hargreaves highlights the innovation in vaccine delivery that could make a difference in providing low- and middle-income countries with vaccination options, as well as offer a boost to programs in higher-income countries. The question to be answered in the future will be how to improve upon existing vaccine technology.
pharmaphorum
FEBRUARY 14, 2022
Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and GlaxoSmithKline’s market-leading Shingrix. The cash will fund a phase 2b trial in 678 people aged over 50 that will compare CRV?101’s
Expert insights. Personalized for you.
52 
Let's personalize your content